Pfizer coronavirus vaccine less effective, still protects against variant from India: French study
- A study by France’s Pasteur Institute found people who had received two doses of Pfizer saw a three-fold reduction in their antibodies against the B. 1.617 variant
- The co-author of the research said the findings show that ‘this variant has acquired partial resistance to antibodies’
“Despite slightly diminished efficacy, the Pfizer vaccine probably protects” against the Indian variant, according to laboratory test results, said Olivier Schwartz, the institute’s director and co-author of the study that was published on the BioRxiv website ahead of peer review.
The study sampled 28 health care workers in the city of Orleans. Sixteen of them had received two doses of the Pfizer vaccine, while 12 had received one dose of the AstraZeneca vaccine.
People who had received two doses of Pfizer saw a three-fold reduction in their antibodies against the Indian variant, B. 1.617, according to the study, but were still protected.
“The situation was different with the AstraZeneca vaccine, which induced particularly low levels of antibodies neutralising” the Indian variant, the study said.
Patients who had Covid-19 within the past year and people vaccinated with two doses of Pfizer retained enough antibodies to be protected against the Indian variant, but three to six times less antibodies than against the UK variant, Schwartz said.
04:12
What do we know so far about the Covid-19 variants?
The study shows that “this variant has acquired partial resistance to antibodies,” Schwartz said.
